People
Simpson Named to Spruce Biosciences Board of Directors
13 November 2017 - - US-based biotechnology company Spruce Biosciences has named Camilla V. Simpson, to the Spruce Biosciences board of directors, the company said.

She is senior vice president and head of product portfolio development at BioMarin Pharmaceutical Inc.

Simpson is responsible for the product development strategy of BioMarin's rare disease portfolio.

Previously, Simpson was group vice president of regulatory affairs at BioMarin, and has 22 years of experience in the industry.

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders.

The Spruce team is leveraging their extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from rare endocrine diseases.

Spruce's lead product candidate, SPR001, has a novel and clinically verified mechanism of action and is currently in Phase 2 clinical trials for congenital adrenal hyperplasia, a rare disease that is screened in newborns and for which there is not yet an FDA-approved therapy.

The company is headquartered in San Francisco and closed a series A Financing of USD 20m in 2016.
Login
Username:

Password: